Complete Performance: Control. Commitment. Confidence.
Now indicated to treat peripheral artery disease (PAD) in the superficial femoral arteries (SFA) and proximal popliteal arteries (PPA), the Complete™ SE Self-Expanding Vascular Stent System promises to become a powerful tool for clinicians when treating complex lesions in the lower extremities. The system incorporates a dual-deployment handle and a triaxial catheter, providing physicians with exceptional deployment accuracy, while also minimizing unexpected stent jumping.
Data from the Complete SE SFA study, which enrolled 196 subjects at 28 sites across Europe and the U.S., resulted in an impressive clinically driven target lesion revascularization (TLR) rate of 8.4%.1 With more than 90% of study subjects not requiring any follow-up procedures after one year, the Complete SE stent demonstrated the fewest amount of reinterventions in the SFA compared to competitor studies.2 There were zero stent fractures at 12 months.3
1Complete SE SFA Study – clinically driven TLR rate
2Compared with SFA studies of Cook Zilver PTX, IDEV SUPERA, Cordis Smart Stent, Bard Lifestent and EV3 Protégé Everflex.
3The Complete SE SFA Study Clinical Update, 18 December 2012
The Complete SE Vascular Stent System may not be approved for the Iliac and SFA/PPA indications in all geographies